Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 7, 2009

Cornerstone Inks $70M Deal for Chiesi Farmaceutici’s Respiratory Distress Syndrome Drug

  • Cornerstone Therapeutics entered a transaction valued at $70 million to obtain rights to Chiesi Farmaceutici’s Curosurf, a drug for respiratory distress syndrome in premature infants. The agreement gives Cornerstone a 10-year license with renewable rights for the U.S., $15.5 million in cash, and first right to offer any new product or technology Chiesi intends to market in the U.S.

    Under the terms of the agreement, Cornerstone will issue 11.9 million shares of common stock. Additionally, Craig Collard, Cornerstone's president and CEO, and Steven Lutz, Cornerstone's evp, manufacturing and trade, will sell an aggregate of 1.6 million shares to Chiesi at $5.50 per share. Chiesi will thus own approximately 51% of Cornerstone's fully diluted common shares outstanding.

    Curosurf, which is a natural lung surfactant, is currently available in over 50 countries including the U.S. and most of Europe. It has reportedly been administered to approximately 1,000,000 infants since 1992.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »